Author(s):
Vikram Gharge, Pranav Bang, Sachin Khopade, Krishna Kinage, Balasaheb Jadhav
Email(s):
Vikram.gharge@zuventus.com
DOI:
10.52711/2231-5675.2025.00006 
Address:
Vikram Gharge, Pranav Bang, Sachin Khopade, Krishna Kinage, Balasaheb Jadhav
Research and Development, Zuventus Healthcare Limited, Hinjawadi, Pune – 411057, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 15,
Issue - 1,
Year - 2025
ABSTRACT:
The stability-indicating method for Deflazacort Suspension was developed using the Analytical Quality by Design (AQbD) approach, focusing on process control and understanding. A multilevel factorial design was used to optimize the gradient mode's time and mobile phase ratio. Sophisticated software like Design Expert and Minitab aided in chromatographic condition optimization. The method utilizes a Zorbax Eclipse XDB C18 column (150mm x 4.6mm, 5µm particle size), with a flow rate of 1.0 mL/min, and monitoring the analyte with a UV/PDA detector at of 245nm wavelength known for its reliability. It employs two mobile phases: A, consisting of Water, Tetrahydrofuran, and Acetonitrile (91:3:6, v/v/v), and B, comprising Water, Tetrahydrofuran, Acetonitrile, and Methanol (4:2:74:20, v/v/v/v). Statistical analysis confirms the importance of these components in achieving effective separation and detecting related substances. The validation of method was done as per ICH guidelines. Linearity, specificity, Limit of Detection (LOD), Limit of Quantification (LOQ), precision, accuracy, solution stability, and robustness parameters were validated. The method was validated to ensure reliability and accuracy, demonstrating linearity from 0.02 to 1.2ppm with a correlation coefficient (r2 > 0.99) at 245nm. This confirms the method's ability to precisely quantify related substances in Deflazacort Suspension. The stability of Deflazacort Oral Suspension was rigorously assessed, including a forced degradation study. Critical system suitability parameters, tailing factor, and theoretical plate, met acceptable limits, confirming the method's efficiency and resolution. Successful separation of degradation peaks from each other and the main peak was achieved during the study. The method's robustness was confirmed with variations under 2%, ensuring consistent and reproducible results despite minor changes in conditions. Peak purity analysis showed no co-eluting peaks, confirming the method's specificity. These findings validate the stability-indicating nature of the chromatographic method for Deflazacort Oral Suspension analysis, ensuring its reliability for quality control.
Cite this article:
Vikram Gharge, Pranav Bang, Sachin Khopade, Krishna Kinage, Balasaheb Jadhav. Development and Validation of related Substances method for Deflazacort Suspension by High Performance Liquid Chromatography using AQbD Approach. Asian Journal of Pharmaceutical Analysis. 2025;15(1):31-9. doi: 10.52711/2231-5675.2025.00006
Cite(Electronic):
Vikram Gharge, Pranav Bang, Sachin Khopade, Krishna Kinage, Balasaheb Jadhav. Development and Validation of related Substances method for Deflazacort Suspension by High Performance Liquid Chromatography using AQbD Approach. Asian Journal of Pharmaceutical Analysis. 2025;15(1):31-9. doi: 10.52711/2231-5675.2025.00006 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2025-15-1-6
REFERENCES:
1. National Center for Biotechnology Information. PubChem Compound Summary for CID 189821, 2023. National Center for Biotechnology Information.
2. Markham A, Bryson HM, Agnusdei D, Lewinson; D, Reeve; J. Drug Evaluation Deflazacort a Review of its Pharmacological Properties and Therapeutic Efficacy.
3. Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular Disorders. 2006 Apr; 16(4): 249–55.
4. Ferraris JR, Pasqualini T, Alonso G, Legal S, Sorroche P, Galich AM, et al. Effects of deflazacort vs. methylprednisone: A randomized study in kidney transplant patients. Pediatric Nephrology. 2007;22(5).
5. Angelini C. The role of corticosteroids in muscular dystrophy: A critical appraisal. Vol. 36, Muscle and Nerve. 2007. p. 424–35.
6. Gonzalez-Castanẽda RE, Castellanos-Alvarado EA, Flores-Marquez MR, Gonzalez-Perez O, Luquin S, Garcia-Estrada J, et al. Deflazacort induced stronger immunosuppression than expected. Clin Rheumatol. 2007; 26(6).
7. Nayak AK. Application of quality by design for the development of biopharmaceuticals. Academic Press. 2019;
8. Bernareggi A, Poletti P, Zanolo G, Zerilli LF. Simultaneous determination of the two main metabolites of deflazacort in human plasma by high-performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis. 1987; 5.
9. Santos-montes a.; gonzalo lumbreras, r.; gasco lopes, a. I; isquierdo hornillos, R. Extraction and High -performance liquid chromatography separation of Deflazacort and its metabolite 21-hydroxydeflazacort. J Chromatogr B Biomed Appl. 1994; 657: 248–53.
10. Reynolds DL, Burmaster SD, Eichmeier LS. Quantitative Determination of 21-Hydroxy-Deflazacort in Human Plasma Using Gradient Semi-Microbore Liquid Chromatography. Biomedical Chromatography. 1994; 8.
11. Hirata H, Kasama T, Sawai Y, Fike RR. Simultaneous determination of deflazacort metabolites II and III, cortisol, cortisone, prednisolone and prednisone in human serum by reversed-phase high-performance liquid chromatography. Journal of Chromatography B. 1994; 658.
12. Ifa D. R.; Moraes M. E.; Moraes M. O.; Santagada V.; Caliendo G.; De Nucci G. Determination of 21-hydroxydeflazacort in human plasma by high performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry. J Mass Spectrom. 2000; 35: 440–5.
13. D.D. Chechare, Y.R. Thombare, S.S. Shinde, N.S. Mhaske, R.D. Khaire. Method Development and Validation of Irbesartan by RP-HPLC. Asian Journal of Pharmaceutical Analysis. 2024; 14(1): 1-0. doi: 10.52711/2231-5675.2024.00002.
14. Scremin A, Piazzon M, Antonio M, Silva S, Kuminek G, Márcia Correa G, et al. Spectrophotometric and HPLC determination of deflazacort in pharmaceutical dosage forms. Vol. 46, Article Brazilian Journal of Pharmaceutical Sciences. 2010.
15. Ambalal PSJPN and SSK Patel. Validated Spectrophotometric Methods for Determination of Deflazacort in Tablet Dosage Form. Asian Journal of Pharmacy and Life Science. 2011;
16. Karthikeyan S, Aji A, Singh S, Puthli S. A lc-ms/ms method for the quantification of deflazacort metabolite in human plasma: development, validation and application to a pharmacokinetic study. Journal of Drug Delivery and Therapeutics [Internet]. 2011; 2013(3): 75. Available from: http://jddtonline.info
17. Patel SA PN. High performance thin layer chromatographic method for estimation of deflazacort in tablet. J Appl Pharm Sci. 2011; 1(7): 94-–8.
18. Özkan Y, Savaşer A, Taş Ç, Uslu B, Özkan SA. Drug dissolution studies and determination of deflazacort in pharmaceutical formulations and human serum samples by RP-HPLC. J Liq Chromatogr Relat Technol. 2003; 26(13).
19. D.D. Chougule NSN. Development and Validation of High-Performance Liquid Chromatographic Method for Estimation of Deflazacort in Pharmaceutical Formulation.Asian J Research Chem. 2011; 140–2.
20. Corrêa GM, Bellé LP, Bajerski L, Borgmann SHM, Cardoso SG. Development and validation of a reversed-phase HPLC method for the determination of deflazacort in pharmaceutical dosage forms. Chromatographia. 2007; 65(9–10).
21. ICH. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use, Pharmaceutical development Q8 (R2). ICH Harmonised Tripartite Guideline. 2009.
22. ICH Expert Working Group. International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use, Topic Q9: Quality Risk Management. ICH Harmonised Tripartite Guideline. 2005.
23. Patel KY, Dedania ZR, Dedania RR, Patel U. QbD approach to HPLC method development and validation of ceftriaxone sodium. Futur J Pharm Sci. 2021; 7(1).
24. Borman P. The application of quality by design to analytical methods. Pharm Tech. 2007; 142–52.
25. Schweitzer M. Implications and opportunities of applying QbD principles to analytical measurements. Pharm Tech. 2010; 52–9.
26. Rajkotwala A. QbD approach to analytical method development and validation of piracetam by HPLC. World J Pharmacy Pharmaceutical. 1771–84.
27. Singh P. QbD Approach for stability indicating HPLC method for determination of artemether and lumefantrine in combined dosage form. Int J Drug Reg Affairs. 2017; 44–59.
28. Prajapati R. QbD approach to HPLC method development and validation for estimation of ftuoxetine hydrochloride and olanzapine in pharmaceutical dosage form. J Emerging Tech Innovative. 2019; 179–95.
29. Borman P, Elder D. Q2 (R1) Validation of Analytical Procedures: text and methodology. ICH Quality Guidelines: An Implementation Guide. 2017 Sep 27: 127-66.